首页>投融资
Maze Therapeutics
D轮
Maze Therapeutics is a biotechnology company focused on developing gene therapies for the potential treatment of cardiovascular and renal disease, including chronic kidney disease and autosomal dominant polycystic kidney disease, metabolic and neurological disorders, including Pompe's disease and amyotrophic lateral sclerosis and eye diseases, including glaucoma and age-related macular degeneration.In January 2022, the company announced a USD 190 million financing.In February 2019, the company raised USD 191 million through financing
基本信息
-
公司全称Maze Therapeutics Inc
-
类型遗传病治疗药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址171 Oyster Point Blvd,Suite 200 SOUTH SAN FRANCISCO CALIFORNIA 94080; US; Telephone: +16508505070;
-
联系电话(650) 850-5070
-
邮箱info@mazetx.com
-
成立时间2018-01-01
投融资
-
2024-12-03D轮1.15亿美元Deep Track CapitalFrazier ManagementJanus Henderson InvestorsLogos CapitalThird Rock VenturesARCH Venture PartnersMatrix Capital ManagementGVGeneral CatalystAndreessen HorowitzForesite CapitalWoodline PartnersCasdin CapitalMoore Strategic Ventures
-
2022-01-10未公开1.9亿美元Matrix Capital ManagementTimefolio CapitalTMCPMoore Strategic VenturesDriehaus Capital ManagementForesite CapitalCity Hill VenturesCasdin CapitalWoodline Partnersa16z Bio+HealthGeneral Catalyst
-
2019-10-23未透露未透露City Hill Ventures
-
2019-02-28A轮1.91亿美元Alexandria Venture InvestmentsThird Rock VenturesCasdin CapitalARCH Venture PartnersForesite Capital
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息